Projects / Programmes source: ARIS

Antiphospholipid syndromes

Research activity

Code Science Field Subfield
3.01.00  Medical sciences  Microbiology and immunology   

Code Science Field
B007  Biomedical sciences  Medicine (human and vertebrates) 
antiphospholipid syndromes, testing for antiphospholipid antibodies, pathogenetic role of antiphospholipid antibodies, therapeutic interventions
Evaluation (rules)
source: COBISS
Researchers (11)
no. Code Name and surname Research area Role Period No. of publicationsNo. of publications
1.  19209  PhD Aleš Ambrožič  Microbiology and immunology  Researcher  2002 - 2004  220 
2.  19258  PhD Tadej Avčin  Human reproduction  Researcher  2002 - 2004  471 
3.  21361  PhD Nataša Gašperšič  Microbiology and immunology  Researcher  2002 - 2004  76 
4.  12154  PhD Maja Hojnik  Microbiology and immunology  Researcher  2001 - 2002  45 
5.  10080  PhD Dušan Logar  Microbiology and immunology  Researcher  2002 - 2004  128 
6.  16184  PhD Martina Plešivčnik Novljan  Microbiology and immunology  Researcher  2002 - 2004  51 
7.  13602  PhD Sonja Praprotnik  Microbiology and immunology  Researcher  2002 - 2004  372 
8.  15441  PhD Uroš Rot  Neurobiology  Researcher  2002 - 2004  185 
9.  07180  PhD Blaž Rozman  Microbiology and immunology  Head  2002 - 2004  563 
10.  06974  MSc Barbara Šajina-Stritar  Human reproduction  Researcher  2002 - 2004  73 
11.  10645  MSc Alenka Šipek Dolničar  Microbiology and immunology  Researcher  2002 - 2004  37 
Organisations (1)
no. Code Research organisation City Registration number No. of publicationsNo. of publications
1.  0312  University Medical Centre Ljubljana  Ljubljana  5057272000  77,669 
The research project will address some critical points in the development and understanding of the antiphospholipid syndromes, which are expected to become the most common systemic autoimmune diseases. A general awareness that different laboratories perform different ELISA methods for the detection of antibodies against the most important protein co-factor ß2-glycoprotein I has led the European expert society to an attempt to standardize these methods (European aPL Forum). Our contribution to these efforst will be an extensive study of certain possible biases regarding the anti-ß2-glycoprotein I ELISA test procedure. Therefore, we will focus on: defining the interactions of the ß2-glycoprotein I antigen with the surface of various microtiter plates, matrix effects and calibration of the measuring system by means of introducing new standards. It is not yet known whether the initiating antigen for antiphospholipid antibodies production is extrinsic, intrinsic or both. These antibodies are likely to participate in or interfere with soluble protein coagulation pathways which is evidently not the only way of their action. The results of our project will elucidate the role of extrinsic - bovine ß2-glycoprotein I (present as a nutrient) to induce an (auto?)antibody response and a possible non-thrombogenic effect of antibodies against ß2-glycoprotein I particularly in patients with atopy. There are several clinical questions concerning possible associations of antiphospholipid antibodies and some rarer clinical manifestations. Important additional observations and new definitions of certain illnesess connected with antibodies against ß2-glycoprotein I are expected from expert clinical groups. It is our aim to study different autoimmune diseases (i.e.: juvenile idiopathic artritis, systemic lupus erythematosus), thrombogenic syndromes (cerebral ischemia under the age of 40 years) and atopies (atopic dermatitis) in order to understand different pathogenic potential of antiphospholipid antibodies, probably depending on different antigenic specificities.
Views history